Pricing a Compounded Rx Program: Margins, Markups, and What Patients Will Pay

Compounded prescriptions typically carry 50–75% gross margins when priced correctly. Your total cost stack — pharmacy cost, shipping, provider fee, and platform fee — usually runs $25–80 per unit. Consumer price points range from $79 (hair/skin) to $349+ (peptides/HRT). Price to the outcome, not the ingredient. Telehealth programs at steady state should hit 60%+ gross margin.

Most operators get pricing wrong in one of two directions: they underprice because they're anchoring on pharmacy cost alone, or they overprice because they're anchoring on whatever the VC-funded platform adjacent to them is charging. Neither is a real benchmark. Your benchmark is the cost of your own stack and the value a patient places on convenience, access, and getting a real provider to approve their treatment.

This is a working teardown. Run these numbers against your actual pharmacy quotes — every figure in this post is directional until you have your own pharmacy contract in hand.

---

What Does a Compounded Rx Actually Cost You? {#cost-stack}

Before you price anything, you need a clean cost stack. Most operators skip this step and just pick a number that feels right. That works until your pharmacy costs change, you add a second fulfillment partner, or your churn model forces you to discount retention orders.

Your cost stack has four lines:

1. Pharmacy (COGS) The actual cost of the compound. This varies enormously by:

• Compound class (sterile vs. non-sterile)
• Ingredient cost (peptides are expensive; topicals are cheap)
• Volume tier (your per-unit cost drops meaningfully at 200+ units/month)
• Pharmacy relationship (503A vs. 503B)

2. Shipping and cold chain Non-sterile topicals: $5–10. Standard compounded capsules or sublingual drops: $6–12. Sterile injectables (peptides, some HRT) requiring cold chain: $15–25 estimated. If your pharmacies offer embedded shipping rates, get those billed as COGS so they don't surprise you later.

3. Provider fee A licensed provider must review and approve every order — that's non-negotiable, and it's also your compliance story. Provider fees on a per-consult basis run $8–20 per async encounter (estimated), depending on whether you're running in-house staff or using a provider network. As your volume scales, this line compresses.

4. Platform and fulfillment infrastructure Whatever you're paying for order routing, your Shopify stack, EHR integration, and fulfillment tooling. At neolife's pricing model, this is a flat monthly fee rather than a per-order skim — which matters a lot at volume, because a per-transaction rake scales against you as you grow.

A simplified cost-stack example (TRT, estimated):

Line	Cost (est.)
Pharmacy — testosterone cypionate 200mg/mL, 10mL vial	$28–40
Shipping (standard)	$8
Provider fee (async consult)	$10–15
Platform/fulfillment	$5–8 (amortized)
Total COGS	$51–71

Price that program at $149/month and you're at a ~52–66% gross margin. Price it at $199/month and you're at 64–74%. That's before any acquisition cost — we'll get to CAC and LTV separately.

---

Category-by-Category Pricing Teardown {#by-category}

Every category has a different cost structure and a different consumer price anchor. Here's how to think through each one.

Men's Health: TRT / Testosterone {#trt}

Pharmacy cost: Moderate. Testosterone cypionate in oil is relatively low-cost at compound pharmacy; the vial size and concentration matter. Expect $28–55 per month of supply (estimated).

Consumer price anchor: Brand testosterone (Androderm patches, Testim gel) at retail runs $150–400/month before insurance. A compounded injectable at $119–189/month is a straight-line value proposition for cash-pay patients.

Typical operator price range: $99–199/month

Margin at the midpoint ($149): 55–65% (estimated)

Watch out for: State-by-state prescribing rules for Schedule III controlled substances. Your provider network needs to be licensed where the patient is located. This is table stakes — your pharmacy and legal counsel should confirm your prescribing coverage map before launch.

---

Women's Health: HRT / Menopause {#hrt}

Pharmacy cost: Wide range. Progesterone capsules are low-cost. Bi-est or Tri-est topical creams are moderate. Pellet therapy is an outlier — ignore it for DTC.

Consumer price anchor: Brand HRT (Premarin, Estrace, Prometrium) has significant insurance coverage in the US, which complicates cash-pay positioning. The DTC pitch here is access and customization — bioidentical formulations in compounded form that a patient can get without a months-long wait for a specialist appointment.

Typical operator price range: $89–249/month depending on formulation

Margin at the midpoint: 60–70% (estimated)

Positioning note: This category rewards education. Women who are already informed about bioidentical HRT convert fast. Those who aren't yet convert slower but retain longer because the benefit is clear once they've experienced it. Price reflects that — don't discount your way in.

---

Hair Loss: Finasteride, Minoxidil, Combination Topicals {#hair}

Pharmacy cost: Low. Compounded finasteride + minoxidil topical is one of the cheapest compounds in the DTC stack. Oral minoxidil is similarly low-cost. Expect $8–18/month per patient (estimated).

Consumer price anchor: This category is more price-sensitive than others because there are multiple OTC alternatives. Hims, Keeps, and others have trained consumers to expect $25–40/month for basic topicals. You can compete at $49–79/month if you're offering a compounded combination formula or a provider-supervised program with regular check-ins.

Typical operator price range: $49–89/month

Margin at $69: 70–80% (estimated) — this is one of your highest-margin categories

Catch: Lower ARPU means you need volume and retention to make hair pencil as a standalone. It works well as an add-on to a primary program (e.g., TRT patients who also want hair loss treatment).

---

ED: Sildenafil, Tadalafil, Trimix {#ed}

Pharmacy cost: Oral compounded sildenafil and tadalafil are very low-cost — among the cheapest compounds you'll run. Trimix (injectable) is more expensive and requires sterile compounding.

Consumer price anchor: Generic sildenafil at retail is now $1–3 per pill from traditional pharmacies. Your value proposition is not price — it's access, discretion, and the provider consultation that's already included. Position around that.

Typical operator price range: $59–129/month (oral); $149–249 (Trimix)

Margin for oral at $89: 75–85% (estimated)

Provider note: Cardiac contraindications require that a licensed provider reviews every patient — not a box-check, but a genuine intake that protects both the patient and your business. Make this loud in your messaging. It's your compliance story and your trust signal at the same time.

---

Skin: Tretinoin, Azelaic Acid, Custom Combinations {#skin}

Pharmacy cost: Non-sterile topicals are low-cost to compound. A tretinoin 0.05% cream or combination formula (tretinoin + niacinamide + azelaic acid) runs $10–20/month (estimated).

Consumer price anchor: DTC tretinoin has been commoditized by Curology, Apostrophe, and others at $30–60/month. Your edge is combination formulas that a patient can't easily get OTC, and provider oversight that's built into the program.

Typical operator price range: $69–119/month

Margin at $89: 70–80% (estimated)

Cross-sell opportunity: Skin programs have excellent multi-product attach. A patient on a tretinoin program is a natural candidate for a hair add-on, or for HRT (if female, late 30s–50s demographic). Build your catalog for cross-sell.

---

Peptides: BPC-157, Sermorelin, PT-141, Others {#peptides}

Pharmacy cost: The highest in this list. Sterile peptide compounds require 503A or 503B pharmacies, and the active pharmaceutical ingredients (APIs) are expensive. Expect $50–120/month depending on peptide (estimated).

Consumer price anchor: There is no true commodity anchor here — patients self-educating on peptides come from longevity forums, not from a mainstream DTC touchpoint. They're sophisticated buyers who will pay for access to a provider-supervised program. This is a premium category.

Typical operator price range: $199–399/month

Margin at $279: 55–70% depending on peptide (estimated)

Compliance note: Peptides are the most legally complex category in this list. FDA has restricted some peptides for compounding use. Any peptide program must be reviewed by your pharmacy and legal counsel before you launch. Do not assume your pharmacy's catalog from 2024 reflects what's permissible today. Verify with counsel.

---

How to Set Your Price: The Framework {#pricing-framework}

Three inputs. Run them in order.

1. Cost floor Your total COGS (pharmacy + shipping + provider + platform). You cannot price below this without losing money on every order.

2. Margin target For a DTC subscription program, 60% gross margin is your minimum healthy target. At 60%, you have room to run CAC payback at a 3–6 month LTV horizon. Below 50%, you're running a fulfillment business, not a brand.

3. Consumer ceiling What will the patient pay? This is not "what can you charge" — it's "what is the patient comparing this to?" For most categories, the comparison is:

• Brand drug retail cost (high anchor)
• Platform competitor price (moderate anchor — check their published pricing)
• Patient's perceived value of access, speed, and convenience

Price at or below the competition on the value axis, not necessarily the dollar axis.

The formula:

Price = Total COGS / (1 - Target Margin %)

If COGS = $60 and target margin = 65%, then minimum price = $60 / 0.35 = $171. Round to the nearest psychologically clean price point: $169, $179, or $189.

---

Subscription vs. One-Time Pricing {#subscription-vs-one-time}

For compounded Rx programs, subscription pricing is almost always the right model. Here's why it matters economically:

• Provider consult is a one-time cost per enrollment, not per refill. That fixed cost amortizes over a longer patient relationship.
• Pharmacy volume discounts are triggered by consistent monthly order volume. Subscriptions stabilize your demand signal.
• LTV is everything. Your CAC/LTV model only works if you can predict monthly revenue per patient. One-time purchases break that model.

Typical subscription structures:

• Month-to-month (higher flexibility, higher churn rate)
• Quarterly pre-pay (10–15% discount; better LTV signal)
• Annual pre-pay (20–25% discount; rare at launch, worth building toward)

Launch month-to-month. Add quarterly once you've validated that patients stay 3+ months.

---

The GLP-1 Pricing Lesson: Don't Anchor on One Category {#glp1-lesson}

The GLP-1 compounding window showed what a price-to-value opportunity looks like: brand semaglutide at $900–1,300/month, compounded at $99–250/month. That gap drove massive patient demand and large operator revenue in 2023–2025.

It also showed what happens when you build a business around a single compound at a single FDA enforcement posture. The compounding window for GLP-1 injectables narrowed sharply in 2025–2026 as the FDA resolved shortage designations, and operators who were 80%+ concentrated in semaglutide had to rebuild their book of business under time pressure.

The lesson is not "avoid weight loss." The lesson is: build a multi-category catalog from day one, so that no single regulatory shift can restructure your entire revenue base. TRT, HRT, hair, ED, skin, and peptide programs give you six independent revenue streams, each with its own patient demographic and its own retention curve.

Compounded prescription pricing, done right, works across all of them. The math is similar. The formularies are different. The business is resilient.

---

What Operators Get Wrong About Margin {#common-mistakes}

Mistake 1: Treating pharmacy cost as the only COGS. Provider fees, shipping, and platform costs are real costs. If you're not including them in your margin calculation, your reported margin is fictional.

Mistake 2: Pricing based on competitor screenshots, not your own cost stack. Your competitor may have a different pharmacy contract, a different provider model, or may be pricing below margin to buy growth. You don't know. Price from your costs.

Mistake 3: Underpricing to "win the patient" and planning to raise later. Subscription pricing is stickier than you think — in both directions. Patients who came in at $99/month resist moving to $149/month, even if the product is unchanged. Set a price you're comfortable holding for 12 months.

Mistake 4: Ignoring shipping as a margin lever. Cold-chain shipping is expensive and often under-modeled. If your pharmacy ships for you and buries the cost in the compound price, get it unbundled. You need to know the real number.

Mistake 5: No system of record for per-order economics. If you're running on a platform that controls your order data, you may not be able to calculate actual per-order margin. Own your order data. If your system of record is the platform's, you're flying blind.

---

Key Takeaways {#key-takeaways}

• Your cost stack has four lines: pharmacy COGS, shipping, provider fee, and platform. All four count.
• Target 60%+ gross margin for a healthy DTC subscription Rx business.
• Hair and skin topicals are your highest-margin categories (70–80% est.); peptides are your lowest (55–70% est.) but command the highest ARPU.
• Price to the patient's alternative (brand drug, specialty pharmacy wait, platform competitor), not to your COGS plus a round number.
• Subscription pricing is not optional — it's the only model that makes CAC economics work.
• Build multi-category from day one. Category concentration is operational risk.
• Provider approval belongs in your pricing story, not just your compliance checklist.

---

FAQs {#faq}

Q: What gross margin should I target for a compounded Rx DTC program? A: 60% is a practical minimum. At 60% gross margin, with reasonable CAC and monthly subscription pricing, most programs can hit payback within 4–6 months per acquired patient. Programs running below 50% gross margin are difficult to scale because there is not enough headroom to absorb acquisition costs, churn, and operational overhead simultaneously.

Q: Should I charge a separate consult fee or bundle it into the subscription? A: Bundle it. A separate consult fee adds friction at the point of conversion, and most patients abandon when they see a two-line checkout (consult fee + prescription fee). Build the provider cost into your monthly price. Make "provider-included" a feature, not an add-on.

Q: How often should I review and update pricing? A: At a minimum, review your cost stack every 6 months and when you renegotiate your pharmacy contract. Ingredient costs, pharmacy overhead, and shipping rates all move. Your price should reflect your actual economics, not a number you set at launch and never revisited.

Q: Can I charge different prices in different states? A: You can, but most operators do not. Uniform national pricing is simpler operationally and avoids patient-facing confusion. Where state-specific rules create real cost differences (e.g., certain compounds require additional provider licensing in specific states), some operators handle that via program availability rather than price variation.

Q: What's the right price for a cash-pay patient vs. someone who has tried to use insurance? A: Compounded prescriptions are almost universally cash-pay — they are not covered by insurance in most cases, and your program should be priced accordingly. The value proposition is access and price relative to the brand drug, not relative to a copay. Your messaging should make clear that most patients pay far less than they would for brand-name alternatives, even without insurance.

---

If you're modeling out your first program's unit economics and want to see how the fulfillment and platform cost line actually fits in, talk to the neolife team. We work with operators from first-program launch through multi-category scale — and we don't take a cut of your order volume.